Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The L1 protein is the major capsid protein of human papillomavirus type 52, a high-risk genotype associated with cervical cancer and other anogenital malignancies. L1 mediates initial attachment and entry of HPV into host cells, stabilizes the viral genome during intracellular trafficking, and is a key component of prophylactic vaccines like Gardasil®9, where it is presented as virus-like particles (VLPs) to induce neutralizing antibodies.
L1 VLPs induce neutralizing antibodies that prevent virus-cell binding and entry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human papillomavirus type 52 major capsid (L1) protein (HPV52 L1).